DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Schmitz-Winnenthal FH, Hohmann N, Niethammer AG. et al
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: a randomized, placebo-controlled, phase 1 trial.
OncoImmunology 2015;
4 (04) e1001217
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.